x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

COR2ED - Oncology Medical Conversation

COR2ED Medical Education

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit

science courses

All Episodes

00:24:55

Precision oncology: An introduction to molecular testing

COR2ED - Oncology Medical Conversation ·

2023/12/06

This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer. Prof. David Hong from MD Anderson Cancer Center, Houston, Texas, USA and Dr Tracy Stockley from the University Health Network, Toronto, Canada discuss optimal testing strategies to identify actionable mutations. The experts discuss genetic testing and why identifying genetic alterations is a critical step to achieving optimal patient care. They share their multidisciplinary perspectives on

en

00:25:27

Breast cancer: Oral SERDs in ER+ BC. Part 2 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments. Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist

en

00:25:27

Breast cancer: Oral SERDs in ER+ BC. Part 2 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment selection and sequencing to maximise outcomes, current data, and what to consider when adjusting dosage or switching treatments. Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of

en

00:16:16

Gastric and GEJ cancers: Clinical case discussions....

COR2ED - Oncology Medical Conversation ·

2023/12/06

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. In the second episode, Dr Klempner presents a case of a patient with advanced/metastatic gastric cancer. The two experts discuss biomarker testing such as MMR, HER2, PD-1 and CLDN 18.2. They also discuss treatment options, CPS

en

00:16:16

Gastric and GEJ cancers: Clinical case discussions....

COR2ED - Oncology Medical Conversation ·

2023/12/06

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. In the second episode, Dr Klempner presents a case of a patient with advanced/metastatic gastric cancer. The two experts discuss biomarker testing such as MMR, HER2, PD-1 and CLDN 18.2. They also discuss

en

00:27:27

Gastric and GEJ cancers: Clinical case discussions....

COR2ED - Oncology Medical Conversation ·

2023/12/06

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. In this first episode, Dr Smyth presents a case of operable localised gastric cancer. The two experts discuss the importance of MMR biomarker testing And CROSS VS FLOT management approaches. They refer

en

00:27:27

Gastric and GEJ cancers: Clinical case discussions....

COR2ED - Oncology Medical Conversation ·

2023/12/06

This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford University Hospitals NHS Foundation Trust, UK) discuss patient cases focusing on gastric and gastroesophageal junction cancer. In this first episode, Dr Smyth presents a case of operable localised gastric cancer. The two experts discuss the importance of MMR biomarker testing And CROSS VS FLOT management approaches. They refer to data from recent

en

00:23:12

Breast cancer: Oral SERDs in ER+ BC. Part 1 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only, oral SERD to be FDA approved. They focus on the efficacy results and landmark analysis not only according to the duration of CDK4/6i prior treatment but also to the presence/absence of ESR1 mutation. Experts also provide a brief discussion on EMERALD trial safety results. The discussion ends with a look at the current treatment landscapeand future perspective for oral SERDs in

en

00:23:12

Breast cancer: Oral SERDs in ER+ BC. Part 1 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only, oral SERD to be FDA approved. They focus on the efficacy results and landmark analysis not only according to the duration of CDK4/6i prior treatment but also to the presence/absence of ESR1 mutation. Experts also provide a brief discussion on EMERALD trial safety results. The discussion ends with a look at the current treatment landscapeand future

en

00:19:44

Prostate cancer: Treatment intensification in mCSPC -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast GU NURSES CONNECT members Brenda Martone and Jennifer Sutton discuss the nurse role in managing treatment intensification for metastatic castration sensitive prostate cancer(mCSPC) patients with triplet therapy of ADT + docetaxel + a novel hormonal agent (NHA). They focus on patient selection, AE management and drug-drug interactions. The experts discuss key data from the PEACE 1 and ARASENS trials of triplet therapy with abiraterone and darolutamide

en

00:19:44

Prostate cancer: Treatment intensification in mCSPC -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

In this podcast GU NURSES CONNECT members Brenda Martone and Jennifer Sutton discuss the nurse role in managing treatment intensification for metastatic castration sensitive prostate cancer(mCSPC) patients with triplet therapy of ADT + docetaxel + a novel hormonal agent (NHA). They focus on patient selection, AE management and drug-drug interactions. The experts discuss key data from the PEACE 1 and ARASENS trials of triplet therapy with abiraterone and darolutamide respectively, in combination with

en

00:21:09

Colorectal cancer: Treatment sequencing in advanced mCRC

COR2ED - Oncology Medical Conversation ·

2023/12/06

This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond. Dr Shubham Pant from MD Anderson Cancer Center, Houston Texas USA and Dr Jenny Seligmann from the University of Leeds, UK discuss treatment considerations in these patients and evaluate recent data. The experts discuss the treatments currently approved at third line – regorafenib and TAS-102 (trifluridine/tipiracil). They also reflect on data

en

00:21:09

Colorectal cancer: Treatment sequencing in advanced mCRC

COR2ED - Oncology Medical Conversation ·

2023/12/06

This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond. Dr Shubham Pant from MD Anderson Cancer Center, Houston Texas USA and Dr Jenny Seligmann from the University of Leeds, UK discuss treatment considerations in these patients and evaluate recent data. The experts discuss the treatments currently approved at third line – regorafenib and TAS-102 (trifluridine/tipiracil). They also reflect on data presented at ASCO GI

en

00:22:48

Prostate cancer: Which mCSPC patients benefit from...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU CONNECT podcast. The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for

en

00:22:48

Prostate cancer: Which mCSPC patients benefit from...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prostate cancer (mCSPC) in this GU CONNECT podcast. The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for all patients and

en

00:22:49

Prostate cancer: PARP inhibitors. Part 3 - Efficacy...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah in the United States discuss the efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented at ASCO GU 2023 and the impact for the treatment of patients with mCRPC in this GU CONNECT podcast. In this

en

00:22:49

Prostate cancer: PARP inhibitors. Part 3 - Efficacy...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, University of Utah in the United States discuss the efficacy and safety data of combination therapy with PARPi and NHAs, incorporating the latest data presented at ASCO GU 2023 and the impact for the treatment of patients with mCRPC in this GU CONNECT podcast. In this podcast, the experts

en

00:24:54

Advanced HCC: Patients not eligible for IO - What are...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist at the David Geffen School of Medicine, both from the USA, discuss the treatment options for advanced hepatocellular carcinoma (HCC) patients who are not eligible for immunotherapy (IO) first line. In this podcast, the experts give an overview of the current systemic treatment options for patients by looking into the results

en

00:24:54

Advanced HCC: Patients not eligible for IO - What are...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Prof. Dr James Harding, Medical Oncologist atMemorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist at the David Geffen School of Medicine, both from the USA, discuss the treatment options for advanced hepatocellular carcinoma (HCC) patients who are not eligible for immunotherapy (IO) first line. In this podcast, the experts give an overview of the current systemic treatment options for patients by looking into the results from different

en

00:19:43

Prostate cancer: PARP inhibitors. Part 2 -...

COR2ED - Oncology Medical Conversation ·

2023/12/06

Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitors and novel hormonal agent (NHA) combinationtherapy for patients with mCRPC, providing both a US and EU perspective. In this podcast, the experts discuss efficacy and safety data from the PROPEL study of olaparib

en

183 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter